Evaluasi Penggunaan Antibiotik pada Community Acquired Pneumonia

I Dewa Agung Ayu Diva Candraningrat; Tri Murti Andayani; Ika Puspita Sari

doi:10.22146/farmaseutik.v20i4.92448

Evaluasi Penggunaan Antibiotik pada Community Acquired Pneumonia

https://doi.org/10.22146/farmaseutik.v20i4.92448

I Dewa Agung Ayu Diva Candraningrat⁽¹⁾, Tri Murti Andayani^(2*), Ika Puspita Sari⁽³⁾

(1) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(2) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Rumah Sakit Akademik Universitas Gadjah Mada/Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract

Community Acquired Pneumonia (CAP) merupakan infeksi yang terjadi di paru-paru yang didapatkan dari komunitas dan sering meningkatkan angka rawat inap di rumah sakit. Bakteri yang paling umum menjadi penyebab CAP adalah Streptococcus pneumoniae, Mycoplasma pneumoniae, dan Chlamydophila pneumoniae. Berdasarkan pada pedoman American Thoracic Society (ATS) dan Infectious Disease Society of America (IDSA), penggunaan terapi antibiotik pada pasien CAP dinilai berdasarkan stabilitas klinisnya. Ulasan artikel ini bertujuan untuk membandingkan hasil evaluasi penggunaan antibiotic yang dilihat dari stabilitas klinis dan keamanannya. Ulasan artikel bertujuan untuk membandingkan hasil penelitian yang diperoleh dari PubMed sebagai literatur dan diagram PRISMA sebagai guideline pada proses seleksi artikel. Berdasarkan hasil ulasan artikel diperoleh 10 artikel yang sesuai dengan topik dan tujuan. Dapat disimpulkan bahwa penggunaan antibiotik golongan betalaktam atau fluorokuinolon memiliki efikasi dan keamanan yang baik untuk pasien CAP

Keywords

evaluasi; antibiotik; Community Acquired Pneumonia

References

Ceccato, A., Cilloniz, C., Ranzani, O. T., Menendez, R., Agusti, C., Gabarrus, A., Ferrer, M., Sibila, O., Niederman, M. S., & Torres, A. (2017). Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. PLOS ONE, 12(6), e0178022. https://doi.org/10.1371/journal.pone.0178022

Figueiredo-Mello, C., Naucler, P., Negra, M. D., & Levin, A. S. (2018). Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: A randomized controlled trial. Clinical Microbiology and Infection, 24(2), 146–151. https://doi.org/10.1016/j.cmi.2017.06.013

File, T. M., Goldberg, L., Das, A., Sweeney, C., Saviski, J., Gelone, S. P., Seltzer, E., Paukner, S., Wicha, W. W., Talbot, G. H., & Gasink, L. B. (2019). Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clinical Infectious Diseases, 69(11), 1856–1867. https://doi.org/10.1093/cid/ciz090

Kaidashev, I., Lavrenko, A., Baranovskaya, T., Blazhko, V., Digtiar, N., Dziublyk, O., Gerasymenko, N., Iashyna, L., Kryvetskyi, V., Kuryk, L., Rodionova, V., Stets, R., Vyshnyvetskyy, I., & Feshchenko, Y. (2022). Etiology and efficacy of anti-microbial treatment for community-acquired pneumonia in adults requiring hospital admission in Ukraine. Acta Biomedica Atenei Parmensis, 93(2), e2022238. https://doi.org/10.23750/abm.v93i2.13137

Kanoh, S., & Rubin, B. K. (2010). Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications. Clinical Microbiology Reviews, 23(3), 590–615. https://doi.org/10.1128/CMR.00078-09

Lakota, E. A., Van Wart, S. A., Trang, M., Tzanis, E., Bhavnani, S. M., Safir, M. C., Friedrich, L., Steenbergen, J. N., Ambrose, P. G., & Rubino, C. M. (2020). Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data. Antimicrobial Agents and Chemotherapy, 64(7), e02263-19. https://doi.org/10.1128/AAC.02263-19

Llor, C., Pérez, A., Carandell, E., García-Sangenís, A., Rezola, J., Llorente, M., Gestoso, S., Bobé, F., Román-Rodríguez, M., Cots, J. M., Hernández, S., Cortés, J., Miravitlles, M., & Morros, R. (2019). Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial. Atención Primaria, 51(1), 32–39. https://doi.org/10.1016/j.aprim.2017.08.003

Lorenzo, M.-J., Moret, I., Sarria, B., Cases, E., Cortijo, J., Méndez, R., Molina, J., Gimeno, A., & Menéndez, R. (2015). Lung inflammatory pattern and antibiotic treatment in pneumonia. Respiratory Research, 16(1), 15. https://doi.org/10.1186/s12931-015-0165-y

LoVecchio, F., Schranz, J., Alexander, E., Mariano, D., Meads, A., Sandrock, C., Moran, G. J., & Giordano, P. A. (2021). Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial. The Journal of Emergency Medicine, 60(6), 781–792. https://doi.org/10.1016/j.jemermed.2021.02.001

Olson, G., & Davis, A. M. (2020). Diagnosis and Treatment of Adults With Community-Acquired Pneumonia. JAMA, 323(9), 885. https://doi.org/10.1001/jama.2019.21118

Pai, M. P., Wilcox, M., Chitra, S., & McGovern, P. (2021). Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial. Respiratory Medicine, 184, 106442. https://doi.org/10.1016/j.rmed.2021.106442

Paukner, S., Sader, H. S., Ivezic-Schoenfeld, Z., & Jones, R. N. (2013). Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010. Antimicrobial Agents and Chemotherapy, 57(9), 4489–4495. https://doi.org/10.1128/AAC.00358-13

Ramirez, J. A., Tzanis, E., Curran, M., Noble, R., Chitra, S., Manley, A., Kirsch, C., & McGovern, P. C. (2019). Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice. Clinical Infectious Diseases, 69(Supplement_1), S33–S39. https://doi.org/10.1093/cid/ciz397

Schweitzer, V. A., Van Smeden, M., Postma, D. F., Oosterheert, J. J., Bonten, M. J. M., & Van Werkhoven, C. H. (2017). Response Adjusted for Days of Antibiotic Risk (RADAR): Evaluation of a novel method to compare strategies to optimize antibiotic use. Clinical Microbiology and Infection, 23(12), 980–985. https://doi.org/10.1016/j.cmi.2017.05.003

Torres, A., Garrity-Ryan, L., Kirsch, C., Steenbergen, J. N., Eckburg, P. B., Das, A. F., Curran, M., Manley, A., Tzanis, E., & McGovern, P. C. (2021). Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. International Journal of Infectious Diseases, 104, 501–509. https://doi.org/10.1016/j.ijid.2021.01.032

Wirz, S. A., Blum, C. A., Schuetz, P., Albrich, W. C., Noppen, C., Mueller, B., Christ-Crain, M., & Tarr, P. E. (2016). Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. European Respiratory Journal, 48(4), 1150–1159. https://doi.org/10.1183/13993003.00474-2016

DOI: https://doi.org/10.22146/farmaseutik.v20i4.92448